Navigation Links
NIH launches trial of investigational genital herpes vaccine
Date:11/8/2013

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

Genital herpes is one of the most common sexually transmitted infections in the United States. Most genital herpes cases are caused by infection with herpes simplex virus type 2 (HSV-2); however, herpes simplex virus type 1 (HSV-1) can also cause genital herpes. An estimated 776,000 people in the United States are infected with HSV-2 or HSV-1 each year. There is no vaccine to prevent genital herpes.

"Although genital herpes is treatable, it is a lifelong infection that can exact a substantial psychological and physical toll on infected individuals and places them at higher risk of acquiring HIV," said NIAID Director Anthony S. Fauci, M.D. "Furthermore, mothers with active genital herpes infection at time of delivery can transmit the virus to their newborns, which can lead to severe illness and death."

"A protective vaccine would help to reduce significantly the spread of this all-too- common sexually transmitted infection," Fauci added.

Led by principal investigator Lesia K. Dropulic, M.D., of NIAID's Laboratory of Infectious Diseases, the trial will test an investigational HSV-2 vaccine candidate, called HSV529, for safety and the ability to generate an immune system response. The investigational vaccine manufactured by Sanofi Pasteur was developed by David Knipe, Ph.D., professor of microbiology and immunobiology at Harvard Medical School, Boston.

Preclinical testing of the candidate vaccine involved a 10-year collaborative effort between Dr. Knipe and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases. The experimental product is a replication-defective vaccine, meaning that scientists have removed two key proteins from the vaccine virus so that it cannot multiply to cause genital herpes.

The clinical trial is expected to enroll 60 adults ages 18 to 40, who will be divided into three groups of 20 participants each. The first group will be of people who have been previously infected with HSV-2 and HSV-1 or solely with HSV-2; the second will have individuals who had been infected with HSV-1 only; and the third will consist of those who have not been infected with HSV-1 or HSV-2. The investigational vaccine is being tested among study participants who have previously been infected with HSV to determine if it may pose any safety issues.

Within each of the three groups, researchers will randomly assign participants to receive three doses (0.5 milliliters each) of the investigational HSV529 vaccine (15 participants) or a saline-based placebo vaccine (five participants). The three vaccinations will occur at study enrollment and again one month and six months later. Participant safety will be monitored throughout the course of the trial, and researchers will follow participants for six months after they have received their last dose of vaccine. Blood samples will be used to evaluate the candidate vaccine's ability to stimulate immune system responses to HSV-2, including production of virus-specific antibodies and T-cell responses. The study is expected to be completed by October 2016.

HSV-2 is generally transmitted through sexual contact and can spread even when the infected individual shows no symptoms. Although HSV-1 commonly infects the mouth and lips, it can also cause genital herpes. Once in the body, HSV migrates to nerve cells and remains there permanently, where it can reactivate to cause painful sores and blisters.


'/>"/>

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. Mayo Clinic launches whole genome breast cancer study
3. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
4. UCLA launches first face transplantation program in western US
5. Georgia Tech launches HomeLab to help companies evaluate home health technologies
6. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
7. K9 CarFence™ Launches as Newest Innovation in Pet Transportation
8. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
9. 'Music Makes It Better' Campaign Launches with Justin Bieber, Victoria Justice, and The Band Perry
10. Fieldtex Products Launches a New Wellness Rewards Service for Companies
11. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2019)... ... June 16, 2019 , ... Ted Danson ... on scientific research for the advancement of medical marijuana-based pharmaceuticals in an upcoming ... listings for more information. , With two investigational new drug applications already accepted ...
(Date:6/14/2019)... ... June 14, 2019 , ... This past Saturday, volunteers from ... dedicated support staff hosted the Parma Heights Day of Giving, where members of underserved ... event through local nonprofits that partnered with the Smiles for Everyone Foundation. ...
(Date:6/13/2019)... ... 13, 2019 , ... Women’s Excellence in Obstetrics and Gynecology specializes in pelvic pain treatment for ... difficult to diagnosis. Women’s Excellence handles routine and complicated pelvic pain conditions including:, ... , Heavy periods , Adhesions (scar tissue) , Interstitial ...
(Date:6/13/2019)... ... June 13, 2019 , ... Pure ... partnership with cannabis delivery company, Driven Deliveries, Inc., the only publicly traded cannabis ... 93% of the population of California with overnight cannabis delivery to major thriving ...
(Date:6/13/2019)... ... June 13, 2019 , ... In two nationally representative ... the United States, the collective impact movement Active Schools aimed to gain ... promoting childhood health and well-being. , The U.S. Department of Health and Human ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... , ... June 13, 2019 , ... ... hospice software has announced the new Smart Scheduling product, part of the HCHB ... HCHB’s Smart Scheduling product uses complex algorithms to create highly efficient routing, mapping ...
(Date:6/13/2019)... ... June 13, 2019 , ... Online laser therapy education portal, ... the public about non-invasive photobiomodulation (PBM) therapy to relieve pain. LTU will host ... the milestone. , Also known as low-level laser therapy (LLLT), PBM ...
(Date:6/13/2019)... ... June 13, 2019 , ... Wellopp , a patient ... outcomes, recently announced the launch of its new community referral services team. , ... customized, local network of community resources focused on improving patients’ social determinants of ...
Breaking Medicine Technology: